$902 Million is the total value of FARALLON CAPITAL MANAGEMENT LLC's 314 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VGIIWS | Exit | VIRGIN GROUP ACQUISIT CORP II*w exp 03/13/202 | $0 | – | -200,000 | -100.0% | 0.00% | – |
| CASWS | Exit | CASCADE ACQUISITION CORP*w exp 11/30/202 | $0 | – | -495,000 | -100.0% | 0.00% | – |
| EDU | Exit | NEW ORIENTAL ED & TECHNOLOGYspon adr | $0 | – | -130,000 | -100.0% | -0.00% | – |
| CMPX | Exit | COMPASS THERAPEUTICS INC | $0 | – | -582,750 | -100.0% | -0.00% | – |
| Exit | DARIOHEALTH CORP | $0 | – | -133,083 | -100.0% | -0.00% | – | |
| VCYT | Exit | VERACYTE INC | $0 | – | -32,500 | -100.0% | -0.00% | – |
| Exit | PATRIA LATIN AMRCN OPPRNTY Aunit 04/22/2026 | $0 | – | -100,000 | -100.0% | -0.01% | – | |
| FATE | Exit | FATE THERAPEUTICS INC | $0 | – | -31,900 | -100.0% | -0.01% | – |
| FOE | Exit | FERRO CORP | $0 | – | -114,963 | -100.0% | -0.01% | – |
| Exit | SOUND POINT ACQUISITION CORPunit 02/25/2027 | $0 | – | -300,000 | -100.0% | -0.02% | – | |
| FGEN | Exit | FIBROGEN INC | $0 | – | -364,764 | -100.0% | -0.02% | – |
| PNT | Exit | POINT BIOPHARMA GLOBAL INC | $0 | – | -626,322 | -100.0% | -0.02% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -169,458 | -100.0% | -0.03% | – |
| ARWR | Exit | ARROWHEAD PHARMACEUTICALS IN | $0 | – | -142,700 | -100.0% | -0.03% | – |
| ZEAL | Exit | ZEALAND PHARMA A/Ssponsored adr | $0 | – | -496,890 | -100.0% | -0.04% | – |
| PBCT | Exit | PEOPLES UNITED FINANCIAL INC | $0 | – | -485,000 | -100.0% | -0.05% | – |
| VGII | Exit | VIRGIN GROUP ACQUISIT CORP II | $0 | – | -1,000,000 | -100.0% | -0.05% | – |
| CAS | Exit | CASCADE ACQUISITION CORP | $0 | – | -990,000 | -100.0% | -0.05% | – |
| ZNGA | Exit | ZYNGA INCput | $0 | – | -1,500,000 | -100.0% | -0.07% | – |
| PACB | Exit | PACIFIC BIOSCIENCES CALIF IN | $0 | – | -1,631,800 | -100.0% | -0.07% | – |
| VNE | Exit | VEONEER INC | $0 | – | -427,500 | -100.0% | -0.08% | – |
| RGEN | Exit | REPLIGEN CORP | $0 | – | -222,979 | -100.0% | -0.20% | – |
| DIDI | Exit | DIDI GLOBAL INCsponsored ads | $0 | – | -16,868,328 | -100.0% | -0.20% | – |
| OCDX | Exit | ORTHO CLINICAL DIAGNOSTICS H | $0 | – | -2,426,913 | -100.0% | -0.22% | – |
| EXAS | Exit | EXACT SCIENCES CORP | $0 | – | -802,898 | -100.0% | -0.27% | – |
| NLSN | Exit | NIELSEN HLDGS PLC | $0 | – | -3,720,000 | -100.0% | -0.49% | – |
| PLAN | Exit | ANAPLAN INC | $0 | – | -1,570,000 | -100.0% | -0.49% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PUB L | $0 | – | -1,480,377 | -100.0% | -0.75% | – |
| AVGO | Exit | BROADCOM INC | $0 | – | -408,850 | -100.0% | -1.24% | – |
| CERN | Exit | CERNER CORP | $0 | – | -3,339,955 | -100.0% | -1.51% | – |
| RTX | Exit | RAYTHEON TECHNOLOGIES CORP | $0 | – | -3,385,484 | -100.0% | -1.62% | – |
| ZNGA | Exit | ZYNGA INCcl a | $0 | – | -44,475,000 | -100.0% | -1.98% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MICROSOFT CORP | 41 | Q3 2023 | 3.7% |
| RADIUS HEALTH INC | 33 | Q2 2022 | 1.7% |
| GRIFOLS S A | 33 | Q4 2021 | 0.9% |
| ALPHABET INC | 32 | Q3 2023 | 4.2% |
| SPDR S&P 500 ETF TR | 31 | Q3 2023 | 25.3% |
| VISA INC | 30 | Q3 2023 | 2.9% |
| WABTEC CORP | 27 | Q3 2023 | 3.6% |
| EXELIXIS INC | 27 | Q3 2023 | 2.8% |
| ELEVANCE HEALTH INC | 26 | Q3 2023 | 2.6% |
| SAVARA INC | 26 | Q3 2023 | 0.3% |
View FARALLON CAPITAL MANAGEMENT LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Atento S.A. | March 15, 2023 | 2,230,357 | 15.4% |
| Metals Acquisition Corp | February 07, 2023 | 2,489,700 | 9.4% |
| Inflection Point Acquisition Corp. | February 06, 2023 | 1,900,000 | 5.8% |
| AMYRIS, INC. | February 24, 2022 | 1,068,904 | 0.3% |
| Swiftmerge Acquisition Corp. | February 14, 2022 | 291,060 | 1.3% |
| Caribou Biosciences, Inc. | February 11, 2022 | 2,428,150 | 4.0% |
| ENANTA PHARMACEUTICALS INC | February 11, 2022 | 287,000 | 1.4% |
| Protagonist Therapeutics, Inc | February 11, 2022 | 387,051 | 0.8% |
| Solid Power, Inc. | February 11, 2022 | ? | ? |
| Better Therapeutics, Inc. | February 09, 2022 | 124,065 | 0.5% |
View FARALLON CAPITAL MANAGEMENT LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR | 2024-02-14 |
| 13F-HR/A | 2024-02-12 |
| SC 13G/A | 2024-02-01 |
| SC 13G/A | 2024-01-23 |
View FARALLON CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.